Pfizer Inc. has joined a worldwide consortium to promote expanded opportunities for personalized cancer medicines.
The pharmaceutical giant, with R&D labs in Groton, became the first drug company to sign onto the Worldwide Innovative Network, based in France.
"Pfizer will play an integral role in shaping the future achievements of this collective group on behalf of cancer patients around the world," WIN said in a statement. "Pfizer's advanced capabilities in the development of targeted oncology therapies will provide a breadth of insights and opportunities to the consortium."
Pfizer's oncology research unit is based in LaJolla, Calif.
For information, go to www.winconsortium.org.